Azitra (AZTR) Accumulated Depreciation (2022 - 2023)
Azitra's (AZTR) quarterly Accumulated Depreciation came in at $401987.0 in Q4 2023, up 40.29% YoY from $286549.0 in Q4 2022, and up 8.48% on a QoQ basis from $370568.0 in Q3 2023.
Azitra (AZTR) Accumulated Depreciation (2022 - 2023) Analysis & Trends
Azitra (AZTR) has 2 years of Accumulated Depreciation data on file, last reported at $401987.0 in Q4 2023.
- Quarterly Accumulated Depreciation rose 40.29% year-over-year to $401987.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $401987.0 (up 40.29% YoY) and the FY2023 annual result came in at $401987.0, up 40.29% from the prior year.
- Accumulated Depreciation climbed to $401987.0 in Q4 2023, from $370568.0 in the prior quarter.
- In the past five years, Accumulated Depreciation ranged from a high of $401987.0 in Q4 2023 to a low of $286549.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 401,987.00 |
| Sep 30, 2023 | 370,568.00 |
| Jun 30, 2023 | 349,531.00 |
| Dec 31, 2022 | 286,549.00 |